Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04198766
Title Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Inhibrx, Inc.
Indications

renal cell carcinoma

lung non-small cell carcinoma

transitional cell carcinoma

head and neck squamous cell carcinoma

Advanced Solid Tumor

melanoma

gastric adenocarcinoma

gastroesophageal adenocarcinoma

Therapies

INBRX-106

INBRX-106 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST